AI and remote monitoring are shaping a new patient journey in oncology
Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting
Lamarca: “Understanding the problem is the first step to solving it”
Career growth is a step-by-step journey, built on resilience, clarity, and the ability to face challenges head-on - because success never happens overnight
Next-generation CAR-T cells are in the pipeline
Novel approaches are being tested to overcome current challenges in the use of cellular therapies such as high toxicity and a complex manufacturing process
The updated ESMO-MCBS captures the evolving treatment landscape and patient priorities
The ESMO-Magnitude of Clinical Benefit Scale has been enhanced to address critical aspects of modern oncology trials, such as novel study designs, quality of life and long-term survival benefits
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Global cooperation is needed to improve trial design and expedite new treatments specifically in low- and middle-income countries
Patient-reported outcomes in dose-finding show value in oncology trial inclusion, but shared standards are needed
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research
Can AI help deliver better medicines to patients?
Artificial intelligence has entered drug discovery and development supporting target identification and validation, but challenges remain
Garassino: “Bridging cultures has shaped my career as a female oncologist”
Reflecting on her transatlantic journey from Italy to the United States of America, Prof. Marina Chiara Garassino shares the key lessons that continue to influence her leadership style
Embracing interdisciplinary collaboration for an AI-driven oncology
ESMO now welcomes members from other disciplines to support and expedite the digital transformation of cancer care
Neoadjuvant PD-1 blockade achieves encouraging clinical response in early-stage dMMR tumours
Findings from a small study support a non-surgical and tumour-agnostic approach with immunotherapy, but further research is needed